Starch/amylose-guest inclusion complexes, a class of supramolecular host-guest assemblies, are of critical importance in the processing, preservation, digestion, nutrients/energy uptake, and health outcomes of starch-containing foods. Particularly, the formation of inclusion complex has been suggested to lower the rate and extent of enzymatic digestion of starch and starch-containing foods. Compared with rapidly digestible starch, starch inclusion complex may fall into the category of slowly digestible starch, providing sustained glucose release and maintaining glucose homeostasis. Therefore, the ability of starch-guest inclusion complex to alter the digestive behavior of energy-dense starchy foods has been of interest to many researchers and has the potential to be developed and formulated into functional foods. In this article, we provide a comprehensive and critical review on the current knowledge of the in vitro and in vivo enzymatic digestion of starch-guest inclusion complexes, by emphasizing the structure-digestibility relationship. We examine the preparation methods employed, crystalline structures obtained, and physicochemical properties characterized in previous reports, which all have implications on the digestive behavior reported on the starch-guest inclusion complexes. In addition, we give suggestions on future research to elucidate the digestive properties of starch-guest inclusion complexes and to develop functional structures based on these complexes for use in foods and nutrition.

As a global public health issue with an increasing prevalence, obesity is related to several metabolic disorders, but is largely preventable. Resistant starch (RS), the indigestible portion of starch, has been studied for its potential effects on reducing obesity. This systematic review aimed to investigate the effect of dietary intake of RS on obesity development and related metabolic profiles in human, including body weight and composition, energy intake and satiety, lipid profiles, blood glucose and insulin, and other blood biomarkers. Eleven peer-reviewed articles published in English between 2000 and 2019 were identified after screening using CENTRAL, MEDLINE, and CINAHL Plus. Based on the results, RS intake had no direct effect on body weight and body composition. Evidence for its effect on reducing energy intake and increasing satiety, as well as improving lipid profiles was inconsistent. Beneficial effects of RS intake on several blood biomarkers were supported, indicating its regulatory roles in blood glucose homeostasis, insulin sensitivity, and gut hormone concentrations. Specifically, five out of the eight articles measuring blood glucose reported a decrease in either fasting or postprandial glucose levels; two out of the three articles measuring insulin sensitivity indicated a significant improvement after RS supplementation; studies measuring gut hormone concentrations including glucagon-like peptide 1 (GLP-1), and peptide YY (PYY) also showed significant improvements after RS interventions. In conclusion, the effect of dietary intake of RS on obesity and its related metabolic complications was not conclusive. Further research with larger sample sizes and longer duration is warranted.

Cardiometabolic risk factors increase the likelihood of cardiovascular disease development by 2-fold. Lycopene, a potent lipophilic antioxidant, may be able to mediate oxidative stress, a mechanism underpinning metabolic syndrome (MetS) and its risk factors. This is, to our knowledge, the first systematic review of the literature with the purpose of investigating the relation between circulating lycopene or dietary intake of lycopene and MetS as well as its risk factors. The review was conducted using PubMed and EBSCOhost databases with the search terms "lycopene" and "metabolic syndrome." Inclusion criteria included human studies published in English in a scholarly, peer-reviewed journal and evaluation of lycopene in relation to ≥3 of the 5 MetS risk factors as defined by the National Cholesterol Education Program's Adult Treatment Panel III (ATP III) report. The process identified 11 studies, including 8 cross-sectional and 3 intervention studies. Cross-sectional studies were grouped into 3 categories, with several studies falling into >1 category, based on results reporting associations of lycopene with the prevalence and outcomes of MetS (5 studies), presence of ATP III risk factors (4 studies), and variables mediating lycopene's influence on MetS risk (3 studies). All studies in each category reported significant protective associations. Of the 3 intervention studies, all reported significant protective effects from a lycopene-rich beverage, despite varying doses and durations of intake. Although a protective relation between lycopene and MetS was generally supported, different MetS components appeared to be influenced by lycopene rather than demonstrating consistent improvement in a single component. Thus, additional research is needed to elucidate the mechanistic effects of lycopene on MetS, as well as to determine evidence-based recommendations concerning dose-durational effects of lycopene and MetS risk reduction. In conclusion, the evidence of lycopene's benefit exists such that lycopene status or lycopene consumption may be associated with favorable alterations to the components of MetS.